







an Open Access Journal by MDPI

Antibody Mediated Rejection in Kidney Transplantation and Incorporation of Newer Non-Invasive Markers in Evaluation and Management

Guest Editors:

Prof. Pradeep V. Kadambi

College of Medicine, University of Florida, Jacksonville, FL, USA

Dr. W James Chon

Missouri School of Medicine, University of Kansas, Kansas City, MO, USA

Deadline for manuscript submissions:

closed (17 April 2021)

Message from the Guest Editors

Kidney transplant is still the best treatment for the management of end-stage kidney disease, and we need to strive to get patients transplanted in a timely manner. Antibody-mediated rejection (AMR) remains elusive both in the short term but especially in the long term. While the conventional approaches of augmenting anti-rejection therapy, plasmapheresis, and anti-B cell agents might be appropriate for acute AMR, there are a still a lot of unknowns. How do we manage chronic AMR? Are there different strategies for management of AMR due to HLA Class I vs. Class II donor-specific antibodies or both? How do we monitor success and long term outcomes? There are lots of guestions with relatively few answers. In recent years, there has been an addition of newer non-invasive markers of active rejection in kidney transplantation. We will specifically focus on donor-derived cell-free DNA (ddcf-DNA) and how we can incorporate this additional noninvasive marker in the evaluation and management of kidney transplant recipients.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed,

MEDLINE, PMC, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General

Medicine)

Contact Us